🔴 Tenaya Therapeutics is trading 5.7% down today after Q2 revenue miss and larger-than-expected loss

Tenaya Therapeutics is trading 5.7% down at $0.74 after its August 5, 2026, second-quarter results missed revenue and loss expectations.

• Collaboration revenue was $1.11 million versus $10.0 million expected; loss was $0.20 per share versus $0.08 expected.
• The loss included a $21.8 million non-cash lease-impairment charge.
• Management retained a cash runway into the second half of 2027 while highlighting TN-201 and TN-401 development progress; positive clinical updates and the broader biotech sector’s 2.09% gain were outweighed by the earnings release.